Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; sodium starch glycollate; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-str is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-str is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; povidone; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-str is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-str is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Irska - engleski - HPRA (Health Products Regulatory Authority)

silver pharma s.l. - mercaptopurine - tablet - 50 milligram(s) - mercaptopurine

Australija - engleski - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - mercaptopurine monohydrate, quantity: 50 mg - tablet - excipient ingredients: pregelatinised maize starch; stearic acid; maize starch; magnesium stearate; lactose - treatment of acute leukaemia. it is of value in remission induction and is particularly indicated for maintenance therapy in acute lymphoblastic leukaemia and acute myelogenous leukaemia.,mercaptopurine-link is also used in the treatment of chronic granulocytic leukaemia.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - allopurinol -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - allopurinol -

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

clinect nz pty limited - allopurinol 100mg;   - tablet - 100 mg - active: allopurinol 100mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

clinect nz pty limited - allopurinol 300mg;   - tablet - 300 mg - active: allopurinol 300mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate sunset yellow aluminium lake - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

Malta - engleski - Malta Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - allopurinol - tablet - allopurinol 300 mg - antigout preparations

Malta - engleski - Malta Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - allopurinol - tablet - allopurinol 300 mg - antigout preparations